Pfizer Inc said that it has completed the sale of its Pfizer Consumer Healthcare business to Johnson & Johnson for $16.6 billion or about $13.5 billion in after-tax proceeds.
"The proceeds from this sale, combined with our strong operating cash flow, give us the flexibility to invest in the growth of our core pharmaceutical business while enhancing total return to shareholders through dividends and share purchases," said Jeffrey B. Kindler, Pfizer chairman and CEO.
Discuss Add this link to... Bury
"The proceeds from this sale, combined with our strong operating cash flow, give us the flexibility to invest in the growth of our core pharmaceutical business while enhancing total return to shareholders through dividends and share purchases," said Jeffrey B. Kindler, Pfizer chairman and CEO.
Discuss Add this link to... Bury
Comments